首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | BTC |
| Uniprot No | P35070 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 32-111aa |
| 氨基酸序列 | DGNSTRSPET NGLLCGDPEE NCAATTTQSK RKGHFSRCPK QYKHYCIKGR CRFVVAEQTP SCVCDEGYIG ARCERVDLFY |
| 预测分子量 | 8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组BTC(Betacellulin)蛋白的3篇参考文献示例(注：部分内容为模拟示例，实际文献请通过学术数据库核实)：
---
1. **文献名称**：*Betacellulin: A novel mitogen from pancreatic β-cell tumors*
**作者**：Shing Y, et al.
**摘要**：该研究首次从小鼠胰腺β细胞瘤中克隆了BTC基因，并通过重组表达验证了其作为表皮生长因子(EGF)家族成员的促细胞分裂活性，揭示了其在胰岛细胞再生中的潜在作用。
2. **文献名称**：*Structural characterization of recombinant human betacellulin and its receptor binding mechanism*
**作者**：Sundaram S, et al.
**摘要**：通过X射线晶体学解析了重组人BTC蛋白的三维结构，阐明了其与EGFR/ErbB4受体的结合模式，为基于BTC的靶向药物设计提供了结构基础。
3. **文献名称**：*Recombinant betacellulin promotes pancreatic β-cell regeneration in diabetic mice*
**作者**：Yamamoto K, et al.
**摘要**：在小鼠糖尿病模型中，重组BTC蛋白通过激活ErbB信号通路显著促进β细胞增殖并改善血糖水平，支持其在糖尿病治疗中的应用潜力。
---
**备注**：以上为示例文献，实际研究中建议通过PubMed或Web of Science检索关键词“recombinant betacellulin”获取最新权威文献。
**Background of Recombinant BTC Protein**
Recombinant BTC (Betacellulin) protein is a member of the epidermal growth factor (EGF) family, known for its role in regulating cell proliferation, differentiation, and tissue repair. Initially identified in pancreatic β-cells, BTC binds to the EGF receptor (EGFR) and ErbB4. activating downstream signaling pathways like MAPK and PI3K/Akt, which are critical for cellular growth and survival. Its unique ability to stimulate β-cell regeneration and insulin secretion has positioned it as a potential therapeutic candidate for diabetes, particularly in promoting pancreatic islet cell recovery.
The production of recombinant BTC involves cloning the BTC gene into expression systems (e.g., *E. coli* or mammalian cells) to ensure proper folding and post-translational modifications. Advances in biotechnological methods have enabled high-purity yields, essential for research and clinical applications. Beyond diabetes, BTC’s role in epithelial tissue repair and its overexpression in certain cancers have spurred studies exploring its dual role in regenerative medicine and oncology.
Research also highlights BTC’s involvement in maintaining intestinal stem cells and aiding mucosal healing, suggesting applications in gastrointestinal disorders. However, its oncogenic potential necessitates careful evaluation in therapeutic contexts. Current studies focus on optimizing delivery mechanisms, such as engineered vesicles or sustained-release formulations, to enhance efficacy while minimizing off-target effects. As a versatile growth factor, recombinant BTC continues to bridge gaps in understanding tissue regeneration and disease mechanisms, holding promise for innovative biotherapies.
×
